Mitral Valve Diseases

Published on 21/06/2015 by admin

Filed under Cardiovascular

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 4756 times

2 Mitral Valve Diseases

Indications

The 2003 ACC/AHA/ASE (American College of Cardiology/American Heart Association/American Society of Echocardiography) Guideline Update for the Clinical Application of Echocardiography lists the various indications for TEE.1 Several of them apply specifically to the MV and they are listed in Table 2-1.

TABLE 2-1 INDICATIONS FOR MITRAL VALVE ASSESSMENT BY TRANSESOPHAGEAL ECHOCARDIOGRAPHY

Class I

Conditions for which there is evidence for and/or general agreement that a procedure be performed or a treatment is of benefit. Class IIa Conditions for which there is a divergence of evidence and/or opinion about the treatment.
Weight of evidence/opinion is in favor of usefulness or efficacy. Class IIb Conditions for which there is a divergence of evidence and/or opinion about the treatment.
Usefulness/efficacy is less well established by evidence or opinion.

LA, left atrium; LA, left atrial; MR, mitral regurgitation.

From the 2003 ACC/AHA/ASE Guideline Update for the Clinical Application of Echocardiography.

Mitral Valve Anatomy (Figure 2-1)

image

Figure 2-1 MV anatomy.

Adapted from Otto CM. Evaluation and management of chronic mitral regurgitation. N Engl J Med. 2001;345:740-746. Reproduced with permission.

Systematic Examination of the Mitral Valve

Regardless of the type of MV disease, the TEE assessment always begins with a systematic two-dimensional (2D) examination of the valve. Using an organized sequence of cross sections, each scallop/segment of the MV is carefully examined for structure and function. The next section describes one sequence of views of the MV. It is important to remember that only the basic views are described here. With increasing experience, echocardiographers make great use of transition images, or images between standard views.

Sequence of Views (Table 2-2 and Figure 2-3)

Three-Dimensional Echocardiography

Three-dimensional (3D) TEE provides exceptional images of the heart. Instead of a plane of information, the computer acquires a volume of data, which can then be reconstructed and viewed from any angle (Figure 2-4). Moreover, the data set can be sliced in any desired plane, much like a computed tomography (CT) scan, in order to re-create 2D images sometimes impossible to obtain by standard 2D echocardiography (Figure 2-5).

The MV, because of its proximity to the TEE transducer, lends itself particularly well to 3D imaging. At this time, 3D remains an adjunct to 2D, but as more centers gain experience with this technology, 3D imaging will become an integral part of intraoperative MV assessment.

The mechanism of MR is usually readily apparent on 3D imaging. Furthermore, off-line MV analysis software packages allow detailed quantification of MV disease, including dimensions, prolapses, and restriction (Figure 2-6). This is very useful in planning the surgical management of MR and may help to identify patients who require specialized surgical care. Moreover, the development of leaflet stress analysis packages opens the door to the possibility of predicting, in the immediate post-bypass stage, the durability of some MV repairs.

Mitral Regurgitation

MR can be due to a structural problem in the valve itself or it may be due to distortion of the valve by external factors, described in Table 2-3.

TABLE 2-3 ETIOLOGY OF MITRAL REGURGITATION

Structural MR

Functional MR MR due to LVOT obstruction

HOCM, hypertrophic obstructive cardiomyopathy; LV, left ventricle; LVOT, left ventricular outflow tract; MR, mitral regurgitation.

Classification of Mitral Regurgitation

Based on leaflet motion: normal, excessive or restricted (Figure 2-7).

Evaluation of Mitral Regurgitation

Step 1: Determine the Mechanism and Localization of Lesions and Etiology

The TEE evaluation of MR requires a comprehensive structural examination of the MV, to determine the mechanism of MR and localization of lesions. This involves a detailed 2D examination described previously. In each cross section, the appearance and integrity of the leaflets is noted: Are the leaflets thickened or calcified? Are they redundant (too much tissue)? Are they intact? One also looks at leaflet motion: Is it normal, excessive, or restricted? The coaptation point is then examined; is it below, at, or above the annular plane? Is there lack of coaptation?

One then proceeds to color Doppler evaluation of the regurgitant jet(s) and spectral Doppler measurements. When available, 3D echocardiography is useful to supplement a comprehensive 2D examination, but in the vast majority of cases, it is not essential to making a diagnosis.

Severity of Mitral Regurgitation

Step 2: Qualitative Assessment

Color Flow Doppler

Color flow Doppler remains the best screening method to diagnose MR. It also allows a semiquantitative assessment of the severity of regurgitation and can provide clues to the mechanism of MR. Pitfall: The appearance of MR by color Doppler is highly dependent on the gain and Nyquist limit of the transducer. Setting the gain too high or the Nyquist limit too low can make the MR appear more severe.

Spectral Doppler

Spectral Doppler provides additional qualitative signs of the severity of MR

Step 3: Quantitative Assessment

There are few true quantitative methods for assessing the severity of MR. They tend to be time-consuming and require various calculations. Because of this, their intraoperative use tends to be limited to research and borderline clinical cases, in which the surgical management depends on the immediate echocardiographic assessment.

Vena Contracta (Figure 2-13)

PISA (Proximal Isovelocity Surface Area) Method (Figure 2-14)

In summary, one can calculate the regurgitant orifice area (ROA) using the following formula:

image

image

Functional Mitral Regurgitation

Functional MR describes a situation in which the mitral leaflets are structurally normal, but failure of coaptation still occurs, resulting in MR. It includes a variety of pathologic states, which have in common LV dilatation and decreased systolic function. The term functional MR is often used interchangeably with ischemic MR, because ischemic heart disease is by far the most common cause of functional MR, but strictly speaking, they are not the same: not all functional MR is ischemic in nature (e.g., idiopathic dilated cardiomyopathy), whereas not all ischemic MR is functional (e.g., a ruptured papillary muscle following a myocardial infarct).

Mechanism of Functional Mitral Regurgitation

Left Ventricular Outflow Obstruction, Systolic Anterior Motion, and Mitral Regurgitation

Mitral Stenosis

Mitral stenosis (MS) is a relatively rare disease in developed countries but it is still the cause of substantial morbidity and mortality worldwide. It was the first cardiac disease to be diagnosed by echocardiography and the first valve disease to be successfully treated surgically.

Evaluation of Mitral Stenosis

Pathophysiologically, chronic inflammation causes leaflet thickening and commissural fusion, leading to the classic “fish mouth” appearance of the valve. Concomitantly, there is fusion and shortening of the subvalvular apparatus results in further decrease in valve mobility. These features are readily visible by echocardiography.

Step 1: 2D Appearance

Because rheumatic MS tends to affect the entire valve, pinpointing the location of disease is often not necessary. Still, a detailed systematic examination of the MV should be performed. Technically, these patients are often difficult to examine: they commonly have severe LA enlargement, which causes rotation of the heart and brings the MV out of alignment with the ultrasound beam. This makes classic TEE cross sections difficult to obtain. The typical 2D echocardiographic findings include

Step 3: Spectral Doppler

The Rest of the Heart: Nonvalvular Indicators of Severe Valvular Disease

MV disease, especially when chronic, has repercussions throughout the heart, usually in the form of LV and LA volume overload as well as pulmonary hypertension and right ventricular (RV) volume/pressure overload. In the context of mitral disease, the following echocardiographic signs suggest significant longstanding valve disease:

Mitral Valve Endocarditis

Echocardiographically, the presence of a vegetation is the hallmark finding in endocarditis and it confirms the diagnosis (Figure 2-24).

Surgical Management of Mitral Valve Disease

Surgical Management of Mitral Regurgitation

The surgical management of MR is surgeon dependent. The current expert consensus is that MV repair is always the treatment of choice for mitral degenerative disease. In experienced hands, it is highly successful with low complication rates and good long-term results. For rheumatic valve disease, the success rate of mitral repair varies among surgeons, but it is still the treatment of choice if feasible. MV replacement is much more common in this patient population. Finally, the surgical management of functional MR is controversial, as described later.

Specifically:

Post-Bypass Assessment in Mitral Valve Procedures

Suggested Readings

1 Quiñones MA, Douglas PS, Foster E, et al. ACC/AHA Clinical Competence Statement on Echocardiography: A Report of the American College of Cardiology/American Heart Association/American College of Physicians–American Society of Internal Medicine Task Force on Clinical Competence. J Am Coll Cardiol. 2003;41:687-708.

2 Shanewise JS, Cheung AT, Aronson S, et al. ASE/SCA guidelines for performing a comprehensive intraoperative multiplane transesophageal echocardiography examination: Recommendations of the American Society of Echocardiography Council for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists Task Force for Certification in Perioperative Transesophageal Echocardiography. Anesth Analg. 1999;89:870-884.

This consensus paper established the standards for performing a comprehensive intraoperative TEE examination. The document also contains recommendations on how to examine the mitral valve by TEE.

3 Lambert AS, Miller JP, Merrick SH, et al. Improved evaluation of the location and mechanism of mitral valve regurgitation with a systematic transesophageal echocardiography examination. Anesth Analg. 1999;88:1205-1212.

This study describes how a systematic TEE examination of the mitral valve can improve the localization of mitral valve regurgitant lesions.

4 Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol. 2003;42:954-970.

This is an update of the 1997 extensive guidelines for the clinical application of echocardiography, including TEE. This document updates the various recommended indications for perioperative TEE.

5 Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography: A report from the American Society of Echocardiography’s Nomenclature and Standards Committee and The Task Force on Valvular Regurgitation. J Am Soc Echocardiogr. 2003;16:777-802.

As its name implies, this is a set of recommendations, based on expert consensus, on how to evaluate regurgitant lesions by echocardiography, both transthoracic and transesophageal.

6 Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009;10:1-25.

These are the latest recommendations of the European Association of Echocardiography (EAE) and American Society of Echocardiography (ASE) for the echo assessment of stenotic valve lesions. They are not specific to TEE.

7 Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2006;48:e1-e148.

This set of guidelines, although not specifically focused on echocardiography, provides the reader with context on the presentation, non-echocardiographic evaluation, and clinical management of congenital and acquired mitral valve disease. A section is also devoted to endocarditis.

8 Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves. J Am Soc Echocardiogr. 2009;22:975-1014.

Although not specifically covered in this chapter, a good understanding of prosthetic valves and their evaluation by echocardiography is essential when dealing with mitral valve disease.

9 Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications. Circulation. 2005;111:3167-3184.

This comprehensive set of recommendations were endorsed by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, the Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and the Societies of Cardiovascular Surgery and Anesthesia, as well as the American Heart Association.

10 Ayres NA, Miller-Hance W, Fyfe DA, et al. Indications and guidelines for performance of transesophageal echocardiography in the patient with pediatric acquired or congenital heart disease: A report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr. 2005;18:91-98.

This extensive document contains guidelines on the performance of TEE in the pediatric congenital heart population, including intraoperative TEE. It includes indications, contraindications, and technical and cognitive skills necessary to safely perform TEE in this population, as well as recommendations about maintenance of skills.

11 Roberts BJ, Grayburn PA. Color flow imaging of the vena contracta in mitral regurgitation: Technical considerations. J Am Soc Echocardiogr. 2003;16:1002-1006.

This manuscript discusses the technical considerations and potential pitfalls surrounding the measurement of the vena contracta in MR.

12 Kahn RA, Mittnacht AJ, Anyanwu AC. Systolic anterior motion as a result of relative “undersizing” of a mitral valve annulus in a patient with Barlow’s disease. Anesth Analg. 2009;108:1102-1104.

This report presents a case of SAM after MV repair and contains a discussion of the various pathophysiologic mechanisms involved in SAM post MV repair.

Share this: